Response rates, duration of response, and dose response effects in phase I studies of antineoplastics, Investigational New Drugs, vol.9, issue.1, pp.115-137, 1991. ,
DOI : 10.1007/BF00194562
Participation in Cancer Clinical Trials, JAMA, vol.291, issue.22, pp.2720-2726, 2004. ,
DOI : 10.1001/jama.291.22.2720
Participants in phase 1 oncology research trials: are they vulnerable? Arch Intern Med, pp.16-20, 2008. ,
Drug development in oncology: classical cytotoxics and molecularly targeted agents, British Journal of Clinical Pharmacology, vol.4, issue.1, pp.15-26, 2006. ,
DOI : 10.1182/blood-2002-05-1361
An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics. Clin Cancer Res, pp.1710-1718, 2010. ,
Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?, Journal of Clinical Oncology, vol.19, issue.1, pp.265-72, 2001. ,
DOI : 10.1200/JCO.2001.19.1.265
Challenges and Pitfalls of Combining Targeted Agents in Phase I Studies, Journal of Clinical Oncology, vol.26, issue.22, pp.3665-3672, 2008. ,
DOI : 10.1200/JCO.2008.17.2676
Méthodes pour la recherche de dose de traitements ciblés : nouvelles pistes, Bull Cancer, vol.97, issue.12, pp.1485-95, 2010. ,
Strategies for optimizing combinations of molecularly targeted anticancer agents, Nature Reviews Drug Discovery, vol.22, issue.8, pp.649-59, 2006. ,
DOI : 10.1038/nrd2089
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia, New England Journal of Medicine, vol.344, issue.14, pp.1031-1038, 2001. ,
DOI : 10.1056/NEJM200104053441401
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors, New England Journal of Medicine, vol.347, issue.7, pp.472-80, 2002. ,
DOI : 10.1056/NEJMoa020461
ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia, Journal of Clinical Oncology, vol.23, issue.18, pp.4100-4109, 2005. ,
DOI : 10.1200/JCO.2005.05.531
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood, pp.473-478, 2002. ,
Cetuximab for the Treatment of Colorectal Cancer, New England Journal of Medicine, vol.357, issue.20, pp.2040-2048, 2007. ,
DOI : 10.1056/NEJMoa071834
Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer, New England Journal of Medicine, vol.359, issue.17, pp.1757-65, 2008. ,
DOI : 10.1056/NEJMoa0804385
Curing metastatic cancer: lessons from testicular germ-cell tumours, Nature Reviews Cancer, vol.275, issue.7, pp.517-542, 2003. ,
DOI : 10.1038/nrc1120
Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee, Clinical Cancer Research, vol.20, issue.16, pp.4210-4217, 2014. ,
DOI : 10.1158/1078-0432.CCR-14-0521
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials, British Journal of Cancer, vol.84, issue.10, p.1424, 2001. ,
DOI : 10.1054/bjoc.2001.1796
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies, Pharmacological Reviews, vol.58, issue.3, pp.621-81, 2006. ,
DOI : 10.1124/pr.58.3.10
Safety and feasibility of targeted agent combinations in solid tumours, Nature Reviews Clinical Oncology, vol.28, issue.3, pp.154-68, 2013. ,
DOI : 10.1038/nrclinonc.2012.245
Dose Escalation Methods in Phase I Cancer Clinical Trials, JNCI Journal of the National Cancer Institute, vol.101, issue.10, pp.708-728, 2009. ,
DOI : 10.1093/jnci/djp079
Pharmacologie des dérivés du platine: différences entre les trois composés et les facteurs de variabilité entre patients, Bull Cancer, vol.98, issue.11, pp.1253-61, 2011. ,
Pazopanib for the Treatment of Metastatic Renal Cell Carcinoma, Clinical Therapeutics, vol.34, issue.3, pp.511-531 ,
DOI : 10.1016/j.clinthera.2012.01.014
Lessons from phase III clinical trials on anti-VEGF therapy for cancer, Nature Clinical Practice Oncology, vol.25, issue.1, pp.24-40, 2006. ,
DOI : 10.1038/ncponc0403
Dose Escalation Methods in Phase I Cancer Clinical Trials, JNCI Journal of the National Cancer Institute, vol.101, issue.10, pp.708-728, 2009. ,
DOI : 10.1093/jnci/djp079
Dose-escalation models for combination phase I trials in oncology, European Journal of Cancer, vol.46, issue.16, pp.2870-2878, 2010. ,
DOI : 10.1016/j.ejca.2010.07.002
Adaptive designs for dual-agent phase I dose-escalation studies, Nature Reviews Clinical Oncology, vol.63, issue.5, pp.277-88, 2013. ,
DOI : 10.1038/nrclinonc.2013.35
Phase I Trial of Pazopanib in Patients with Advanced Cancer. Clin Cancer Res, Jun, vol.1515, issue.12, pp.4220-4227, 2009. ,
Pazopanib: A novel multitargeted tyrosine kinase inhibitor, Current Oncology Reports, vol.23, issue.16S, pp.115-124, 2007. ,
DOI : 10.1007/s11912-007-0007-2
Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor. The Oncologist, 2010. ,
Intérêt du pazopanib dans le traitement des cancers du rein et des sarcomes des tissus mous, Bull Cancer, vol.101, issue.6, pp.641-647, 2014. ,
Concise Drug Review: Pazopanib and Axitinib. The Oncologist, pp.1081-1090, 2012. ,
Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer, Xenobiotica, vol.84, issue.5, pp.443-53, 2013. ,
DOI : 10.3109/00498254.2012.734642
Concise Drug Review: Pazopanib and Axitinib. The Oncologist, pp.1081-1090, 2012. ,
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update, European Journal of Cancer, vol.49, issue.6, pp.1287-96 ,
DOI : 10.1016/j.ejca.2012.12.010
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.369, issue.8, pp.722-753, 2013. ,
DOI : 10.1056/NEJMoa1303989
Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study, Journal of Clinical Oncology, vol.32, issue.14, pp.1412-1420, 2014. ,
DOI : 10.1200/JCO.2013.50.8267
Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer, Journal of Clinical Oncology, vol.28, issue.22, pp.3562-3571, 2010. ,
DOI : 10.1200/JCO.2009.26.9571
Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors, Molecular Cancer Therapeutics, vol.11, issue.8, pp.1820-1828, 2012. ,
DOI : 10.1158/1535-7163.MCT-11-0997
Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2), British Journal of Pharmacology, vol.379, issue.2, pp.898-908, 2010. ,
DOI : 10.1111/j.1476-5381.2009.00569.x
The mechanism of renal clearance of cisplatin (cis-dichlorodiammine platinum II) and its modification by furosemide and probenecid, Biochemical Pharmacology, vol.31, issue.13, pp.2243-2249, 1982. ,
DOI : 10.1016/0006-2952(82)90108-3
Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis, Am J Physiol -Ren Physiol, vol.270, issue.4, pp.700-708, 1996. ,
Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy, Current Opinion in Supportive and Palliative Care, vol.2, issue.1, pp.28-34, 2008. ,
DOI : 10.1097/SPC.0b013e3282f44a75
Mechanisms of cisplatin-induced ototoxicity and prevention, Hearing Research, vol.226, issue.1-2, pp.157-67, 2007. ,
DOI : 10.1016/j.heares.2006.09.015
Aprepitant: drug-drug interactions in perspective, Annals of Oncology, vol.21, issue.12, pp.2316-2339, 2010. ,
DOI : 10.1093/annonc/mdq149
Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting, Cancer Chemotherapy and Pharmacology, vol.68, issue.1, pp.75-83, 2008. ,
DOI : 10.1007/s00280-008-0713-y
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting, Cancer, vol.42, issue.9, pp.2290-300, 2003. ,
DOI : 10.1002/cncr.11320
Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients, Cancer Chemotherapy and Pharmacology, vol.36, issue.6, pp.609-625, 2005. ,
DOI : 10.1007/s00280-004-0946-3
Aprepitant: drug-drug interactions in perspective, Annals of Oncology, vol.21, issue.12, pp.2316-2339, 2010. ,
DOI : 10.1093/annonc/mdq149
Predicting benefit from anti-angiogenic agents in malignancy, Nature Reviews Cancer, vol.8, issue.8, pp.626-661, 2006. ,
DOI : 10.1038/nrc1946
Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.28, issue.3, pp.475-80, 2010. ,
DOI : 10.1200/JCO.2008.21.6994
Population pharmacokinetics of total and unbound plasma cisplatin in adult patients, British Journal of Clinical Pharmacology, vol.38, issue.6, pp.756-63, 2004. ,
DOI : 10.1046/j.1365-2125.1996.04231.x
Pharmacokinetics of pazopanib administered in combination with bevacizumab, Cancer Chemotherapy and Pharmacology, vol.37, issue.Suppl 1, pp.1189-96 ,
DOI : 10.1007/s00280-014-2455-3
Analysis for platinum in biological material by flameless atomic absorption spectrometry, Clin Chem, vol.23, issue.7, pp.1245-1254, 1977. ,
Evaluation of Utility of Pharmacokinetic Studies in Phase I Trials of Two Oncology Drugs. Clin Cancer Res, pp.6039-6082, 2013. ,
A COMBINED APPROACH TO DRUG METABOLISM AND TOXICITY ASSESSMENT, Drug Metabolism and Disposition, vol.34, issue.3, pp.495-503, 2006. ,
DOI : 10.1124/dmd.105.008458
The Effect of an Individual's Cytochrome CYP3A4 Activity on Docetaxel Clearance, Clin Cancer Res, vol.6, issue.4, pp.1255-1263, 2000. ,
Aprepitant for Erlotinib-Induced Pruritus, New England Journal of Medicine, vol.363, issue.4, pp.397-405, 2010. ,
DOI : 10.1056/NEJMc1003937
Cisplatin Pharmacokinetics Using a Five-Day Schedule During Repeated Courses of Chemotherapy in Germ Cell Tumors, Therapeutic Drug Monitoring, vol.17, issue.1, pp.25-32, 1995. ,
DOI : 10.1097/00007691-199502000-00005
Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC) ASCO Meet Abstr, p.3048, 2010. ,